- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Vicore Pharma Holding AB - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| VICORE PHARMA HOLDING AB ADR Aktie jetzt für 0€ handeln | |||||
| Mi | Vicore Pharma Holding: Increase in Number of Shares and Votes in Vicore Pharma | 277 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 30, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists... ► Artikel lesen | |
| 24.09. | Vicore Pharma auf dem Stifel 2026 Virtual Immunology and Inflammation Forum: Neuer Ansatz bei IPF | 1 | Investing.com Deutsch | ||
| 17.09. | Vicore Pharma Holding: Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum | 293 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 17, 2026 / Vicore Pharma Holding AB (publ) (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of... ► Artikel lesen | |
| 01.09. | Vicore Pharma Holding: Vicore Pharma to Participate in Upcoming Healthcare Conferences | 382 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 1, 2026 / Vicore Pharma Holding AB (STO:VICO))(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs... ► Artikel lesen | |
| 26.08. | Vicore Pharma Holding: Vicore Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference | 397 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class... ► Artikel lesen | |
| 24.08. | Vicore Pharma Holding: Vicore Pharma to Present at the European Respiratory Society Congress 2026 | 408 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 24, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class... ► Artikel lesen | |
| 21.08. | Vicore Pharma Holding AB - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 21.08. | Vicore Pharma Holding AB (publ) GAAP EPS of SEK -0.51, revenue of SEK 2.2M | 1 | Seeking Alpha | ||
| 21.08. | Vicore Pharma Holding AB - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.08. | Vicore Pharma Holding AB Q2 Loss Increases | 1 | RTTNews | ||
| 21.08. | Vicore Pharma Holding AB: Interim Report April - June 2026 | 303 | GlobeNewswire (Europe) | Stockholm, Sweden & Cambridge, Mass., August 21, 2026 - Vicore Pharma Holding AB (Nasdaq Stockholm: VICO, Nasdaq US: VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel... ► Artikel lesen | |
| 09.07. | XFRA NEW INSTRUMENTS AVAILABLE ON 09.07.2026 | 1.032 | Xetra Newsboard | The following instruments on XETRA do have their first trading 09.07.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 09.07.2026
Aktien
1 US78392B2060 SK Hynix Inc. ADR
2... ► Artikel lesen | |
| 07.07. | Vicore Pharma Holding: Vicore Pharma to Participate in the Leerink Therapeutics Forum | 461 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of... ► Artikel lesen | |
| 06.07. | Vicore Pharma Holding AB - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 06.07. | Citigroup Inc.: Citi Appointed as Depositary Bank for Vicore Pharma Holding AB's ADR Program | 1.803 | Business Wire | Citi Issuer Services, acting through Citibank N.A., has been appointed by Vicore Pharma Holding AB ("Vicore Pharma"), a clinical-stage biopharmaceutical company unlocking the potential of a new class... ► Artikel lesen | |
| 06.07. | Vicore Pharma Holding: Vicore Pharma Appoints Rob Slack as Chief Scientific Officer | 466 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 6, 2026 / Vicore Pharma Holding (STO:VICO) - Dr. Slack brings over 20 years' experience in fibrosis and respiratory translational science and joins from GSK, where... ► Artikel lesen | |
| 06.07. | Vicore Pharma Holding AB: Vicore Pharma Appoints Rob Slack as Chief Scientific Officer | 290 | GlobeNewswire (Europe) | Dr. Slack brings over 20 years' experience in fibrosis and respiratory translational science and joins from GSK, where he served as Vice President and Head of Respiratory Biology
Stockholm, Sweden &... ► Artikel lesen | |
| 01.07. | Vicore Pharma Holding: Vicore Pharma to Commence Trading in the United States on the Nasdaq Stock Market | 1.301 | ACCESS Newswire | STOCKHOLM, SE AND CAMBRIDGE, MA / ACCESS Newswire / July 1, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a clinical-stage biopharmaceutical company unlocking the potential... ► Artikel lesen | |
| 02.06. | Vicore Pharma Holding: Vicore Pharma to Host Webcast to Discuss Buloxibutid and the Evolving IPF Treatment Landscape | 397 | ACCESS Newswire | STOCKHOLM, SE AND CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 (AT2) receptor agonists... ► Artikel lesen |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,940 | -1,01 % | 90 Milliarden US-Dollar bis 2030: Wie Bayer, Mesoblast und NurExone regenerative Medizin unterschiedlich entwickeln | ||
| MERCK KGAA | 136,90 | +1,82 % | Merck Aktie | Wichtige Durchschnittslinien durchbrochen | Analyse | ||
| NOVO NORDISK | 33,210 | -0,48 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| ETON PHARMACEUTICALS | 55,42 | 0,00 % | Eton Pharmaceuticals, Inc. - 8-K, Current Report | ||
| SANOFI | 71,08 | -0,03 % | Laufende Fusionskontrollverfahren: Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald) | Datum der Anmeldung:24.09.2026Aktenzeichen:B3-102/26Unternehmen:Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald)Produktmärkte:Arzneimittel... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 13,685 | -0,04 % | Generate Biomedicines, Inc.: Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of 'Armored' CAR T Therapy for Ovarian Cancer | Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical... ► Artikel lesen | |
| SEAPORT THERAPEUTICS | 18,420 | 0,00 % | Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each | WASHINGTON (dpa-AFX) - Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range. The company... ► Artikel lesen | |
| PFIZER | 24,735 | +0,18 % | Litfulo and tilrekimig data bolster Pfizer's immunology plans | ||
| LB PHARMACEUTICALS | 37,080 | +0,24 % | Needham initiates LB Pharmaceuticals stock with buy rating | ||
| ELI LILLY | 1.019,20 | +0,33 % | Eli Lilly's Jaypirca gains additional indication for untreated leukemia, lymphoma | ||
| BIOHAVEN | 12,870 | 0,00 % | Biohaven Ltd.: Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 | Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on... ► Artikel lesen | |
| SCHOTT PHARMA | 24,550 | +0,82 % | Aktien Frankfurt: Dax macht Verluste wett - Ölpreis und Anleiherenditen im Fokus | FRANKFURT (dpa-AFX) - Der deutsche Aktienmarkt hat sich am Dienstagnachmittag von seinen Anfangsverlusten vollständig erholt. Eine leichte Entspannung bei den Ölpreisen und bei den Anleiherenditen... ► Artikel lesen | |
| NOVARTIS | 124,98 | -0,14 % | CH-Verlauf: Fester dank Novartis und Nestlé, Roche fallen ab | Zürich - Der Schweizer Aktienmarkt ist mit Schwung in die neue Woche gestartet und hat die Marke bei 14'000 klar zurückerobert. In der Folge konnte er indes dieses Niveau nicht ganz halten. Gestützt... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,555 | +0,11 % | Aquestive appoints Rich Daly to board of directors | ||
| GILEAD SCIENCES | 128,68 | +0,09 % | Assembly Biosciences: Herpes-Countdown mit Gilead |
Das Unternehmen VICORE PHARMA HOLDING AB ADR kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,050 (+0,63 %) liegt der Kurs bei 8,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VICORE PHARMA HOLDING AB ADR finden Sie auf Wallstreet Online.